PMID: 8186058Feb 1, 1994Paper

Plasma protein binding displacement interactions--why are they still regarded as clinically important?

British Journal of Clinical Pharmacology
P E Rolan

Abstract

No abstract listed.

References

Jan 1, 1978·Annual Review of Pharmacology and Toxicology·R D Myers
Jan 1, 1977·Drugs·J M Hansen, L K Christensen
Feb 1, 1979·Pharmacology, Biochemistry, and Behavior·J D Edwards, D A Eckerman
Jul 1, 1978·Clinical Pharmacology and Therapeutics·M GibaldiP J McNamara
Mar 4, 1976·The New England Journal of Medicine·J Koch-Weser, E M Sellers
Nov 1, 1977·Clinical Pharmacology and Therapeutics·S M PondD N Wade
Feb 5, 1976·The New England Journal of Medicine·J Koch-Weser, E M Sellers
Oct 1, 1975·Clinical Pharmacology and Therapeutics·G R Wilkinson, D G Shand
Jun 1, 1992·International Clinical Psychopharmacology·D G Grahame-Smith
Dec 1, 1991·Arthritis and Rheumatism·C F StewartW E Evans
Jul 1, 1989·Clinical Pharmacokinetics·J M Collins, J D Unadkat
Aug 15, 1988·Biochemical Pharmacology·A G Clark, P Debnam
Oct 1, 1987·Archives of Disease in Childhood·N Speight
Jan 1, 1985·Social Science & Medicine·J Lilja
Jan 1, 1986·Clinical Pharmacology and Therapeutics·S ToonD A Goulart
Sep 2, 1971·The New England Journal of Medicine·J K Weser, E Sellers
Jun 1, 1973·European Journal of Clinical Pharmacology·J P TillementE Singlas
Apr 1, 1971·Annals of Internal Medicine·P F GrinerC L Odoroff
Jul 6, 1971·Annals of the New York Academy of Sciences·E M Sellers, J Koch-Weser
Nov 1, 1969·Clinical Pharmacology and Therapeutics·D G LieglerV T Oliverio
Oct 15, 1970·The New England Journal of Medicine·E M Sellers, J Koch-Weser
Mar 2, 1967·The New England Journal of Medicine·P M AggelerP E Kowitz
Dec 1, 1983·British Journal of Clinical Pharmacology·C BanfieldM Rowland
Dec 1, 1980·Clinical Pharmacology and Therapeutics·E PeruccaA Crema
Apr 1, 1981·Journal of Pharmacokinetics and Biopharmaceutics·L J Aarons, M Rowland
Jan 1, 1981·European Journal of Clinical Pharmacology·E M Faed
Mar 1, 1980·The Journal of Clinical Investigation·R A O'ReillyW Howald
Apr 20, 1964·JAMA : the Journal of the American Medical Association·S L FOX

❮ Previous
Next ❯

Citations

Dec 17, 1997·Movement Disorders : Official Journal of the Movement Disorder Society·E DupontE Dorflinger
Sep 5, 2012·European Journal of Clinical Pharmacology·Hossein KhaliliSimin Dashti-Khavidaki
Jan 1, 1997·European Journal of Clinical Pharmacology·D TürckJ Hoffmann
Sep 25, 2012·The Protein Journal·Jolanta Sochacka, Wojciech Baran
Jan 26, 2011·Canadian Journal of Anaesthesia = Journal Canadien D'anesthésie·Ashraf A DahabaHelfried Metzler
Nov 15, 2012·Clinical Pharmacokinetics·Jason A RobertsJeffrey Lipman
Feb 1, 1996·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·D L DriscollW D Klohs
Oct 24, 2002·Biochemical Pharmacology·Nicole A KratochwilPaul R Gerber
Oct 3, 2003·Journal of Chromatography. B, Analytical Technologies in the Biomedical and Life Sciences·Eliza N FungYau Yi Lau
Dec 2, 2010·Nature Reviews. Drug Discovery·Dennis A SmithEdward H Kerns
Jul 19, 2006·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·C Lindsay DeVane
Jun 26, 2002·Journal of Veterinary Pharmacology and Therapeutics·M MartinezD Conner
Dec 18, 2002·Journal of Veterinary Pharmacology and Therapeutics·P L Toutain, A Bousquet-Melou
May 1, 1995·British Journal of Clinical Pharmacology·B CenniB Betschart
Feb 13, 1999·Journal of Clinical Pharmacology·J C LinD B Marcus
Sep 6, 2005·Environmental Health Perspectives·Andrew M Geller, Harold Zenick
Apr 3, 2014·PloS One·Katrina W LexaMatthew P Jacobson
May 31, 2002·Clinical Pharmacokinetics·Bernd MeibohmHartmut Derendorf
Oct 9, 2003·Clinical Pharmacokinetics·Hans Lennernäs
Mar 4, 2011·Clinical Pharmacokinetics·Mary Pat KnadlerRichard Bergstrom
Jan 1, 2011·Journal of Community Hospital Internal Medicine Perspectives·Yan Ji, Youssef Hokayem
May 8, 2014·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Marios ChrysanthakopoulosAnna Tsantili-Kakoulidou
Mar 13, 2014·Cancer Chemotherapy and Pharmacology·Islam R YounisWilliam P Petros
Jul 6, 2014·Clinical Pharmacokinetics·Chiaki Tanaka
Dec 13, 2012·Journal of Cardiovascular Pharmacology·Masanori AbeMasayoshi Soma
Sep 13, 2008·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Yasuyuki KatayamaHiroaki Horigome
Jun 4, 2011·Expert Opinion on Drug Metabolism & Toxicology·Mario PellegattiDimitri Colato
Dec 2, 2008·Expert Opinion on Drug Metabolism & Toxicology·Leonid M Berezhkovskiy
Jul 8, 2010·Expert Opinion on Drug Metabolism & Toxicology·Pietro PalatiniSara De Martin
Mar 7, 2013·Expert Opinion on Drug Discovery·Theodosia VallianatouAnna Tsantili-Kakoulidou
Mar 30, 2005·Expert Opinion on Drug Safety·Elizabeth M Williamson
Mar 8, 2005·Drug Metabolism Reviews·Shufeng ZhouYu-Zong Chen
May 8, 2013·Journal of Pharmaceutical Sciences·Jules HeubergerHartmut Derendorf
Jan 11, 2012·Molecular Aspects of Medicine·Gabriella FanaliPaolo Ascenzi

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Epigenetics Insights from Twin Studies

Find the latest research on epigenetics and twin studies here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Myocardial Stunning

Myocardial stunning is a mechanical dysfunction that persists after reperfusion of previously ischemic tissue in the absence of irreversible damage including myocardial necrosis. Here is the latest research.